ISRCTN16975505已完成未知

Clinical study of effects of oral administration of bulleyaconitine A in postherpetic neuralgia

Xinhua Hospital affiliated with Shanghai Jiaotong University School of Medicine0 个研究点目标入组 120 人开始时间: 2018年11月21日最近更新: 2018年12月10日

试验速览

暂无简介。

•1. Subjects voluntarily signed the informed consent
•2. Patients suffering from postherpetic neuralgia aged from 18 to 80 regardless of gender
•3. Moderate to severe pain, VAS> 4 points or more, or burst pain> 3 times/day
•4. Patients can follow the drug dose and follow-up plan
•5. Patients can describe the symptoms, no serious infection, respiratory insufficiency and has the ability to cooperate
•6. Non-allergic persons
•7. No drug abuse or drug addiction
•8. Non-lactating, non-pregnant women, subjects who did not have a pregnancy plan within 1 month after the test
•9. Patients did not participate in a drug test within 3 months before this test (including the test drug)

•1. Researchers think that there is any reason participant should be excluded
•2. In poor situation, severe systemic infection or respiratory dysfunction and uncooperative
•3. Suffering from severe respiratory system, cardiovascular system diseases, liver and kidney dysfunction, cancer
•4. Patients who are allergic to bulleyaconitine A
•5. Patient who has or a history of drug abuse
•6. Breastfeeding, gestational women or subjects who do not have a pregnancy plan within 1 month after the test
•7. Patients who participated in a drug trial within 3 months before this trial
•8. Patients does not meet the inclusion criteria

发起方

Xinhua Hospital affiliated with Shanghai Jiaotong University School of Medicine